LRGUK Activators are a collection of chemical compounds that, through their influence on cellular signaling pathways, enhance the functional activity of the protein LRGUK. For instance, Forskolin and IBMX both serve to augment intracellular levels of cAMP, a critical second messenger for numerous cellular functions, thereby potentially enhancing LRGUK's role within these functions by promoting downstream signaling cascades in which LRGUK participates. Similarly, Epigallocatechin gallate, by inhibiting various protein kinases, may relieve negative regulatory influences on pathways involving LRGUK, allowing for an increase in its functional activity. PMA, through the activation of protein kinase C, and Sphingosine-1-phosphate, through its receptor-mediated signaling, both contribute to the potential enhancement of pathways that regulate LRGUK activity. Anandamide, by binding to cannabinoid receptors, can influencemultiple signaling pathways, potentially enhancing the activity of LRGUK by promoting cellular processes associated with the protein.
In addition to the aforementioned molecules, LY294002 and U0126 both act as inhibitors to key signaling components, PI3K and MEK1/2 respectively, and by doing so, these inhibitors may indirectly bolster the activity of LRGUK by shifting the balance towards LRGUK-activating pathways. Thapsigargin and A23187 both increase intracellular calcium levels, with the former inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase and the latter acting as a calcium ionophore. The elevation of intracellular calcium can lead to the activation of calcium-dependent pathways, which are known to enhance the functional activity of LRGUK. Bisindolylmaleimide I, as a specific PKC inhibitor, may also indirectly promote LRGUK activity by modulating signaling pathways and thus favoring those that LRGUK is involved in. Finally, SN-38 induces a cellular response to DNA damage that includes signaling pathways potentially contributing to the enhancement of LRGUK activity, illustrating a unique route through which LRGUK may be activated in response to cellular stress. Collectively, these LRGUK Activators, through their targeted effects on various biochemical signaling mechanisms, facilitate the enhancement of LRGUK-mediated functions within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, resulting in an increase in cyclic AMP (cAMP) levels, a second messenger crucial for the regulation of cellular functions. Elevated cAMP can enhance LRGUK activity by promoting downstream signaling cascades that LRGUK is a part of. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased levels of cAMP and cGMP by preventing their degradation. This can potentiate signaling pathways that, when activated, increase the activity of LRGUK. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate (EGCG) inhibits several protein kinases, potentially reducing negative regulatory influences on pathways that LRGUK is involved in, thereby allowing for an enhanced functional activity of LRGUK. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate a multitude of proteins and influence numerous signaling pathways. PKC activation can lead to an enhancement of the pathways that regulate LRGUK activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate interacts with its receptors to activate a variety of intracellular signaling pathways, including those that may converge on the regulation of LRGUK, leading to its enhanced functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that impedes the PI3K/AKT pathway, which can lead to an increase in activity of other signaling pathways that are positively regulated by LRGUK, thus indirectly enhancing LRGUK activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which in turn downregulates the MAPK/ERK pathway. Inhibition of this pathway could shift the balance towards signaling pathways that activate LRGUK or require LRGUK for full activation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin elevates intracellular calcium levels by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). The resultant increase in intracellular calcium can activate pathways that enhance the functional activity of LRGUK. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of PKC. By selectively inhibiting PKC, it can modulate signaling pathways, potentially leading to the upregulation of alternative pathways that enhance the activity of LRGUK. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels, activating calcium-dependent signaling pathways. This activation can enhance the signaling processes that LRGUK is involved in, leading to an increase in its functional activity. | ||||||